Q2 2017 · —
Revenue$249.00K$249.00K no prior Q2 2016 on file+77.9% vs Q1 2017
Net Income-$9.17M-$9.17M N/M vs Q2 2016N/M vs Q1 2017
EPS Diluted-$36.21-$36.21 N/M vs Q2 2016N/M vs Q1 2017
Operating Income-$10,165,000—
Operating Cash Flowderived-$8,877,000—
Margins · derived
Operating margin-4082.3%
Net margin-3682.3%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2017 | Q2 2016 |
|---|---|---|
| Revenue | $249.00K | — |
| Net Income | -$9.17M | -$6.06M |
| EPS Diluted | -$36.21 | -$25.30 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR